加载中
NASDAQHealthcareBiotechnology
最新数据
US$6.99
−US$0.065 · -0.92%
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
收盘时
US$6.99
−US$0.065 · -0.92%
盘后
US$6.99
US$0.00 · 0.00%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
日内区间
当前US$6.99
52周区间
当前US$6.99
盘中时间采用ET。市场数据可能有所延迟。
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
日内区间
当前US$6.99
52周区间
当前US$6.99
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 279.7万 USD | 3891.3万 USD | 2600.4万 USD | 1.11亿 USD | 8507.7万 USD |
| 销货成本 | — | — | — | 203.7万 USD | — |
| 毛利 | 279.7万 USD | 3891.3万 USD | 2600.4万 USD | 1.09亿 USD | 8507.7万 USD |
| 研究与开发 | 5803.4万 USD | 4510.5万 USD | 7126万 USD | 7237.7万 USD | 6873.6万 USD |
| 销售、一般及管理费用 | 3146.8万 USD | 3012.6万 USD | 4045万 USD | 2386.2万 USD | 2093.8万 USD |
| 营业费用 | 8950.2万 USD | 8281万 USD | 1.12亿 USD | 9420.2万 USD | 8967.4万 USD |
| 利息收入 | 657.9万 USD | 738.6万 USD | 496.4万 USD | — | — |
| 利息支出 | — | — | 283.3万 USD | 303.1万 USD | 284.4万 USD |
| 折旧和摊销 | 295.9万 USD | 115.1万 USD | 84.3万 USD | 128.7万 USD | 125.2万 USD |
| 营业利润 | −8670.5万 USD | −4389.7万 USD | −8641.6万 USD | 1453.8万 USD | −459.7万 USD |
| 净利润 | −1.3亿 USD | −7742.4万 USD | −2.2亿 USD | 3537.9万 USD | −2568.7万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$25.00
上涨空间 257.65%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2024年4月5日 | 1:30 | — | — |
已生效 2024年4月5日
1:30
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI349.21万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM242.11万0.00%787.4亿 USD0.19%US$277.9-0.37%
Janus Henderson Small Cap Growth Alpha ETFJSML158.07万0.44%3.61亿 USD0.30%US$86.7888-0.79%
Vanguard Extended Market ETFVXF157.51万0.00%954亿 USD0.05%US$233.52-0.63%
iShares Micro-Cap ETFIWC29.49万0.02%13.17亿 USD0.60%US$181.66-0.73%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM18万0.15%1.17亿 USD0.73%US$15.8484-0.58%
iShares Russell 2000 Growth ETFIWO11.98万0.00%139.17亿 USD0.24%US$353.71-0.86%
Vanguard Russell 2000 Value ETFVTWV10.16万0.01%14亿 USD0.06%US$185.97+0.08%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMJanus Henderson Small Cap Growth Alpha ETFJSMLVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 Value ETFVTWVAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。